 Selective vivo removal rheumatoid factor extracorporeal treatment device rheumatoid arthritis patients prospective phase II trial feasibility tolerance efficacy device selective removal rheumatoid factor plasma rheumatoid arthritis patients device hydrogel-coated plates human immunoglobulin immunoaffinity column patients underwent weekly plasmapheresis treatments primary therapy phase trial patients current rheumatoid arthritis medications dose adjustments patients treatments primary therapy patients eligible apheresis treatment weeks maintenance therapy serious untoward side effects course study treatments different patients complaints dizziness angioedema chest tightness shortness breath significant decrease serum iron significant changes complete blood count serum electrolytes renal hepatic function tests trial clinical efficacy patients morning stiffness time fatigue global pain assessment significant objective improvements joint pain tenderness number affected joints One-half treated patients percent improvement objective measures antirheumatic activity